, Volume 4, Issue 1, pp 79-84,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 12 Jan 2008

UCB Pharma research day—25 October 2007 ‘Glia-neuron interactions and purinergic receptors in neurological disorders’

This is an excerpt from the content

UCB Pharma asked Geoffrey Burnstock to propose a programme of 8 international leaders in the glia-neuron interaction and purinergic signalling field to participate in a meeting aimed at introducing the topic to about 30 members of the Company to consider the therapeutic potential of purinergic signalling compounds for the treatment of neurological disorders, including: epilepsy, neurodegenerative diseases, movement disorders, neuroprotection, mood disorders and neuropathic pain.

Geoff Burnstock, acting as the Chairman of this 1-day meeting, held at the Château de Limelette, Belgium, introduced the objectives of the meeting. He stressed the sophisticated biology that was involved in drug development and the advantages of collaborations between basic scientists, clinicians and the drug industry in bringing advances in knowledge from basic science to application in clinical medicine for the treatment of disease.

The morning session was devoted to the mechanisms underlying glia-neuron intera